RecruitingNCT00500123
The Alpha-1 Foundation's and University of Florida's Alpha-1 Coded Testing (ACT) Study
Sponsor
University of Florida
Enrollment
50,000 participants
Start Date
Jan 1, 2001
Study Type
OBSERVATIONAL
Conditions
Summary
The Alpha-1 Coded Testing (ACT) Study was established to study genetic testing and outcomes of individuals at risk for alpha-1 antitrypsin deficiency.
Eligibility
Inclusion Criteria1
- Individuals of any age at risk for alpha-1 antitrypsin deficiency on the basis of symptoms or family genetic risk.
Exclusion Criteria1
- Any person who has already had genotype and AAT level testing completed and has a qualified result.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
PROCEDUREAlpha-1 Antitrypsin Genotype
Home fingerstick testing for alpha-1 antitrypsin genotype
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT00500123
Related Trials
A Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD)
NCT0755548319 locations
A Study of AIR-001 in Adults With Alpha-1 Antitrypsin Deficiency (AATD)
NCT074311124 locations
A Study to Evaluate the Safety and Efficacy of BEAM-302 in Adult Patients With Alpha-1 Antitrypsin Deficiency (AATD)
NCT0638987711 locations
Gene Therapy for Alpha 1- Antitrypsin Deficiency
NCT069967561 location
PiMZ Longitudinal Cohort (PiMZ Logic)
NCT065056035 locations